This publication provides concise notions about the general knowledge of two contemporary enemies of mankind: coronavirus and cancer. The purpose of this article is to highlight how the weakening of…
Leggi Tutto...
Current data suggest that COVID-19 is less frequent in children, with a milder course. However, an increase in the number of children with a phenotype resembling Kawasaki disease has been observed over the past weeks. The aim of the current minireview is to recapitulate the current discoveries on children and adolescents affected by the recent outbreak of Kawasaki disease and to evaluate a potential association with SARS-CoV-2 infection.
Favipiravir (Avigan), has been proposed as a potential treatment against COVID-19. Pertinent experimental evidence is here summarized, and clinical trials registered up to June 28 listed.
Literature analysis and translation by: Claudia Foray and Sonia Fanelli Reviewed by: Alda Rocca – COVID-19 infection is usually associated with fever and respiratory symptoms. Neurological aspects related to SARS-CoV-2 are still poorly understood, but it is now clear that the virus affects not only the broncho-pulmonary system, but also other body compartments, including the central and peripheral nervous system (CNS, PNS). In this review, we report several subtypes of neurological disorders, observed in SARS-CoV-2 patients, grouped under the name of Guillain-Barré syndrome.
The current pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) typically present with fever and respiratory illness, but some patients also report gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain. In this article, we analyze the main gastrointestinal aspects of the disease.
It is now consolidated that environmental factors, like infections, play an important role in the development and progression of many autoimmune diseases, such as narcolepsy is thought to be. Increased susceptibility to narcolepsy is associated to common upper airway infections, like those caused by Streptococcus pyogenes and by influenza A virus, as well as to some vaccine preparations against H1N1, even if with much lower confidence. This link highlights an important translational medicine opportunity: the current COVID-19 pandemic may be a setting where interdisciplinary research can uncover further mechanistic insight into the early biological events that shape the development of narcolepsy in susceptible individuals.
Since the beginning of COVID-19 outbreak, the attention has mainly focused on the respiratory manifestations of the disease. Several studies in the past have shown that several coronaviruses have neuroinvasive potential. As COVID-19 continues to spread globally, an increasing number of evidence shows that also the SARS-CoV2 could be involved in mechanisms that cause CNS injury or worsen pre-existent CNS pathologies. Thus, neuroimaging screening would be critical for early detection of CNS injuries in COVID patients. However, to date not many imaging studies are available and more of them are needed to validate the efficacy of neuroimaging in revealing COVID-19 associated CNS injuries.